Cadrenal Therapeutics (CVKD)

• Market cap: $15.2M
• 1 day: -6.46%
• 5 days: -12.25%
• 1 month: -4.82%
• 3 months: -13.53%
• 6 months: -50.08%
• Year to date: -11.05%
• 1 year: -66.56%
• 5 years: -89.45%
• 10 years: -89.45%
• Sector: Healthcare
• Industry: Biotechnology

About: Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.

Employees: 4